Shengkai Cao

Title: Shengkai Cao: Innovator in Oral Transmucosal Drug Delivery

Introduction

Shengkai Cao is a notable inventor based in Xiamen, China. He has made significant contributions to the field of pharmaceutical technology, particularly in drug delivery systems. His innovative work focuses on enhancing the bioavailability and palatability of medications.

Latest Patents

Shengkai Cao holds a patent for an oral transmucosal film designed for delivering doxepin through the buccal or sublingual mucosa. This invention features a bilayer structure that includes a mucoadhesive layer containing amorphous doxepin and a soluble backing layer without doxepin. The formulation ensures satisfactory bioavailability and improved palatability for users. The mucoadhesive layer comprises 0.5-25% (w/w) of doxepin, 50-96% of one or more film-forming agents, 1-30% (w/w) of one or more adhesives, and 0.05-5% (w/v) of one or more stabilizers. The backing layer consists of 80-100% (w/w) of one or more film-forming agents. Preferred adhesives include povidone, carbomer, and polycarbophil, while preferred stabilizers include butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), citric acid, and ascorbic acid.

Career Highlights

Shengkai Cao is associated with Xiamen LP Pharmaceutical Co., Ltd., where he continues to develop innovative pharmaceutical solutions. His work has been instrumental in advancing drug delivery technologies, particularly for medications that require rapid absorption and effectiveness.

Collaborations

Shengkai Cao collaborates with notable colleagues such as Liyan Xie and Yuantao Song. Their combined expertise contributes to the development of cutting-edge pharmaceutical products.

Conclusion

Shengkai Cao's contributions to oral transmucosal drug delivery exemplify the importance of innovation in the pharmaceutical industry. His work not only enhances the effectiveness of medications but also improves patient experience.